Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP, GM, Dermatology US | March 25, 2026 | March 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date March 25, 2026 · Filed March 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,882 |
Reported balance
After 2026-03-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-25 · Tax withholding · Disposed 537 · Balance 14,882 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2: This includes an aggregate of 11,160 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.
F2: This includes an aggregate of 11,160 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2026 Filed Mar 26, 2026 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 537 | $92.23 | $49,527.51 |
DisclosureSEC source: 0002015975-26-000006 · wk-form4_1774556029.xml · nonDerivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,882 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 11,160 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 8,542 | $0.00 Strike: $106.21 | $0.00 |
DisclosureSEC source: 0002015975-26-000002 · wk-form4_1769029513.xml · derivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,542 Underlying: Common Stock · 8,542 shares Expires 2036-01-15 F1 · derivative.exercise_date: Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 11,841 | $0.00 Strike: $68.25 | $0.00 |
DisclosureSEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · derivative · entry 4 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,841 Underlying: Common Stock · 11,841 shares Expires 2035-07-14 F5 · derivative.exercise_date: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 13,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · derivative · entry 3 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,154 Underlying: Common Stock · 13,154 shares Expires 2028-07-15 F4 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 5,261 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · nonDerivative · entry 2 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,016 F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including the July 15, 2025 grant, this includes an aggregate of 13,117 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:03 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 182 | $68.25 | $12,421.50 |
DisclosureSEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · nonDerivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,755 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 21:05 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 537 | $62.08 | $33,336.96 |
DisclosureSEC source: 0001628280-25-015196 · wk-form4_1743109504.xml · nonDerivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,937 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 8,517 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 21:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 5,371 | $0.00 Strike: $71.93 | $0.00 |
DisclosureSEC source: 0000879169-25-000033 · wk-form4_1737579977.xml · derivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,371 Underlying: Common Stock · 5,371 shares Expires 2035-01-16 F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 5,921 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0000879169-24-000135 · wk-form4_1721233714.xml · derivative · entry 2 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,921 Underlying: Common Stock · 5,921 shares Expires 2034-07-14 F3 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000135 · wk-form4_1721233714.xml · nonDerivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,474 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 10,474 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 17:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 21,868 | $0.00 Strike: $57.48 | $0.00 |
DisclosureSEC source: 0000879169-24-000066 · wk-form4_1711559063.xml · derivative · entry 2 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,868 Underlying: Common Stock · 21,868 shares Expires 2034-03-25 F3 · derivative.exercise_date: The March 25, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 17:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000066 · wk-form4_1711559063.xml · nonDerivative · entry 1 Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,828 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the March 25, 2024 RSU Grant, this includes an aggregate of 7,828 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.